Tarsus Pharmaceuticalsinc Stock Net Income
| TARS Stock | USD 38.73 0.49 1.28% |
Tarsus PharmaceuticalsInc fundamentals help investors to digest information that contributes to Tarsus PharmaceuticalsI's financial success or failures. It also enables traders to predict the movement of Tarsus Stock. The fundamental analysis module provides a way to measure Tarsus PharmaceuticalsI's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Tarsus PharmaceuticalsI stock.
| Last Reported | Projected for Next Year | ||
| Net Loss | -107.6 M | -102.2 M | |
| Net Loss | -55.9 M | -53.1 M | |
| Net Loss | -135.9 M | -129.1 M | |
| Net Loss | (4.62) | (4.39) | |
| Net Income Per E B T | 0.90 | 0.80 |
Tarsus | Net Income |
Tarsus PharmaceuticalsInc Company Net Income Analysis
Tarsus PharmaceuticalsI's Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current Tarsus PharmaceuticalsI Net Income | (135.89 M) |
Most of Tarsus PharmaceuticalsI's fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Tarsus PharmaceuticalsInc is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Tarsus Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Tarsus PharmaceuticalsI is extremely important. It helps to project a fair market value of Tarsus Stock properly, considering its historical fundamentals such as Net Income. Since Tarsus PharmaceuticalsI's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Tarsus PharmaceuticalsI's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Tarsus PharmaceuticalsI's interrelated accounts and indicators.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Tarsus Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Tarsus PharmaceuticalsInc reported net income of (135.89 Million). This is 139.82% lower than that of the Pharmaceuticals sector and 294.01% lower than that of the Health Care industry. The net income for all United States stocks is 123.8% higher than that of the company.
Tarsus Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Tarsus PharmaceuticalsI's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Tarsus PharmaceuticalsI could also be used in its relative valuation, which is a method of valuing Tarsus PharmaceuticalsI by comparing valuation metrics of similar companies.Tarsus PharmaceuticalsI is currently under evaluation in net income category among related companies.
Tarsus PharmaceuticalsI ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Tarsus PharmaceuticalsI's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Tarsus PharmaceuticalsI's managers, analysts, and investors.Environmental | Governance | Social |
Tarsus PharmaceuticalsI Institutional Holders
Institutional Holdings refers to the ownership stake in Tarsus PharmaceuticalsI that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Tarsus PharmaceuticalsI's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Tarsus PharmaceuticalsI's value.| Shares | Nantahala Capital Management, Llc | 2023-12-31 | 750.6 K | State Street Corporation | 2023-12-31 | 674.8 K | Artisan Partners Limited Partnership | 2024-03-31 | 627.4 K | Geode Capital Management, Llc | 2023-12-31 | 609.7 K | Vivo Capital, Llc | 2024-03-31 | 565.5 K | Ikarian Capital, Llc | 2023-12-31 | 518.5 K | Goldman Sachs Group Inc | 2023-12-31 | 474.9 K | Ensign Peak Advisors Inc | 2023-12-31 | 437.9 K | Dimensional Fund Advisors, Inc. | 2024-03-31 | 424.8 K | Rtw Investments, Llc | 2023-12-31 | 3.2 M | Blackrock Inc | 2023-12-31 | 2.5 M |
Tarsus Fundamentals
| Return On Equity | -0.66 | ||||
| Return On Asset | -0.35 | ||||
| Operating Margin | (1.36) % | ||||
| Current Valuation | 1.18 B | ||||
| Shares Outstanding | 37.78 M | ||||
| Shares Owned By Insiders | 8.66 % | ||||
| Shares Owned By Institutions | 91.34 % | ||||
| Number Of Shares Shorted | 7.66 M | ||||
| Price To Book | 6.90 X | ||||
| Price To Sales | 77.74 X | ||||
| Revenue | 17.45 M | ||||
| Gross Profit | (17.76 M) | ||||
| EBITDA | (142.28 M) | ||||
| Net Income | (135.89 M) | ||||
| Cash And Equivalents | 245.36 M | ||||
| Cash Per Share | 9.20 X | ||||
| Total Debt | 31.73 M | ||||
| Debt To Equity | 0.09 % | ||||
| Current Ratio | 21.36 X | ||||
| Book Value Per Share | 7.29 X | ||||
| Cash Flow From Operations | (117.49 M) | ||||
| Short Ratio | 14.77 X | ||||
| Earnings Per Share | (4.75) X | ||||
| Price To Earnings To Growth | 0.28 X | ||||
| Target Price | 57.38 | ||||
| Number Of Employees | 244 | ||||
| Beta | 1.11 | ||||
| Market Capitalization | 1.44 B | ||||
| Total Asset | 266.22 M | ||||
| Retained Earnings | (244.66 M) | ||||
| Working Capital | 219.19 M | ||||
| Net Asset | 266.22 M |
About Tarsus PharmaceuticalsI Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Tarsus PharmaceuticalsInc's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Tarsus PharmaceuticalsI using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Tarsus PharmaceuticalsInc based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Tarsus PharmaceuticalsI
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Tarsus PharmaceuticalsI position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Tarsus PharmaceuticalsI will appreciate offsetting losses from the drop in the long position's value.Moving against Tarsus Stock
| 0.49 | MIRA | MIRA Pharmaceuticals | PairCorr |
The ability to find closely correlated positions to Tarsus PharmaceuticalsI could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Tarsus PharmaceuticalsI when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Tarsus PharmaceuticalsI - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Tarsus PharmaceuticalsInc to buy it.
The correlation of Tarsus PharmaceuticalsI is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Tarsus PharmaceuticalsI moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Tarsus PharmaceuticalsInc moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Tarsus PharmaceuticalsI can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Tarsus PharmaceuticalsI Piotroski F Score and Tarsus PharmaceuticalsI Altman Z Score analysis. You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
Complementary Tools for Tarsus Stock analysis
When running Tarsus PharmaceuticalsI's price analysis, check to measure Tarsus PharmaceuticalsI's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tarsus PharmaceuticalsI is operating at the current time. Most of Tarsus PharmaceuticalsI's value examination focuses on studying past and present price action to predict the probability of Tarsus PharmaceuticalsI's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tarsus PharmaceuticalsI's price. Additionally, you may evaluate how the addition of Tarsus PharmaceuticalsI to your portfolios can decrease your overall portfolio volatility.
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account |
Is Tarsus PharmaceuticalsI's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Tarsus PharmaceuticalsI. If investors know Tarsus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Tarsus PharmaceuticalsI listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.75) | Revenue Per Share 1.35 | Quarterly Revenue Growth 10.046 | Return On Assets (0.35) | Return On Equity (0.66) |
The market value of Tarsus PharmaceuticalsInc is measured differently than its book value, which is the value of Tarsus that is recorded on the company's balance sheet. Investors also form their own opinion of Tarsus PharmaceuticalsI's value that differs from its market value or its book value, called intrinsic value, which is Tarsus PharmaceuticalsI's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Tarsus PharmaceuticalsI's market value can be influenced by many factors that don't directly affect Tarsus PharmaceuticalsI's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Tarsus PharmaceuticalsI's value and its price as these two are different measures arrived at by different means. Investors typically determine if Tarsus PharmaceuticalsI is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Tarsus PharmaceuticalsI's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.